| JOURNAL HOME | CME HOME | THIS MONTH | PAST ISSUES | ETOC | COLLECTIONS |
| AUTHORS | REVIEWERS | EDITORIAL BOARD | FEEDBACK | RSS | HELP |
 
|
|
|
||
|
|
© 1999 International Anesthesia Research Society
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
We conducted this study to evaluate whether there is an association between preoperative drug therapy and in-hospital mortality in patients undergoing coronary artery graft surgery. We collected data on 1593 consecutive patients undergoing coronary artery surgery. The relative risk of in-hospital mortality was determined by logistic regression with in-hospital mortality as the dependent variable, and independent variables that included known risk factors and preoperative cardioactive or antithrombotic drug treatment, i.e., age; left ventricular function; left main coronary artery disease; urgent priority; gender; previous cardiac surgery; concurrent cardiovascular surgery; chronic lung disease; creatinine concentration; hemoglobin concentration; diabetes; hypertension; cerebrovascular disease; recent myocardial infarction; prior vascular surgery; number of arteries bypassed; and regular daily treatment with ß-blockers, aspirin within 5 days, calcium antagonists, angiotensin converting enzyme (ACE) inhibitors, digoxin, or warfarin. In-hospital mortality was 3.3%. The relative risk of in-hospital mortality (with 95% confidence intervals of the relative risk) associated with the following drug treatments was: nitrates 3.8 (1.5–9.6), ß-blockers 0.4 (0.2–0.8), aspirin within 5 days 1.0 (0.5–1.9), calcium antagonists 1.1 (0.6–2.1), ACE inhibitors 0.8 (0.4–1.5), digoxin 0.7 (0.2–1.8), and warfarin 0.3 (0.1–1.6). We conclude that in-hospital mortality is positively associated with preoperative nitrate therapy and negatively associated with ß-adrenergic blocker therapy. A significant association between in-hospital mortality and the preoperative use of calcium antagonists, ACE inhibitors, aspirin, digoxin, and warfarin was not confirmed.
Implications: We examined the association between common drug treatments for ischemic heart disease and short-term survival after cardiac surgery using a statistical method to adjust for patients' preoperative medical condition. Death after surgery was more likely after nitrate therapy and less likely after ß-blocker therapy.
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Although many drugs used to treat cardiovascular disease have been proven effective for control of symptoms, knowledge of their effect on survival is incomplete. For example, it has been suggested that calcium antagonists may increase the mortality rate in patients with hypertension (1) and ischemic heart disease (2,3). The safety of other cardiovascular drugs, such as nitrates, has also been reevaluated (4–6).
Cardiac surgical patients may be at increased risk of the adverse effects of drug treatment. Patients requiring coronary artery surgery tend to have more severe cardiac disease, and the perioperative period is characterized by surgical stress, hemodynamic changes, and potential for the interaction with other drugs administered perioperatively. In addition, many regular drug treatments are ceased or interrupted, which exposes the patient to the possibility of drug withdrawal. Moreover, these patients are exposed to myocardial ischemia, myocardial dysfunction, and major changes in thrombotic status.
Although some investigators have suggested digoxin (7), IV inotropes (8), or IV nitrates (8) as markers of patients with reduced left ventricular function and unstable angina, there are little data that systematically examines the influence of preoperative drug therapy on early mortality in coronary artery surgery. One reason for this has been the confounding effects of other risk factors that influence outcome; for example, old age, emergency surgery, previous cardiac surgery, and reduced left ventricular function. However, many studies have delineated the important preoperative patient factors that influence mortality after coronary artery surgery (7–13). Therefore, it is now possible to take these into account when evaluating the effect of preoperative drugs.
The aim of this study was to determine whether there is an association, independent of other known risk factors, between commonly administered preoperative cardiovascular drug therapy and in-patient mortality in patients presenting for coronary artery surgery and, if so, to estimate the strength of that association. Alterations in thrombotic status have also been postulated to mediate some adverse effects of medications, such as calcium antagonists and nitrates; therefore, we have included preoperative antithrombotic drugs in our assessment.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Our study included all patients who underwent coronary artery bypass grafting between March 18, 1993 to June 18, 1998, with or without concurrent cardiac or cardiovascular surgery, at Sir Charles Gairdner Hospital.
Typical operative management is described in the following section, although there were variations depending on clinical indications. Therapy with preoperative cardioactive drugs was continued until the morning of surgery. Patients were anesthetized with fentanyl (15–20 µg/kg) and enflurane. Monitoring included computerized ST segment display and a flow-directed pulmonary artery catheter. Cardiopulmonary bypass (CPB) was instituted with a roller pump and membrane oxygenator (Capiox, Terumo, Tokyo) with hypothermia to 28°C, aortic cross-clamping, and intermittent cold blood cardioplegia. A centrifugal pump (Biomedicus; Medtronic, Minneapolis, MN) was used for patients undergoing repeat cardiac surgery and combined valve and graft surgery. Aprotinin was used, in various doses, for some patients with recent exposure to aspirin and many patients scheduled for repeat cardiac surgery. Proximal anastomoses were performed after removal of the cross-clamp. At the completion of surgery, patients were mechanically ventilated in an intensive care unit. Patients undergoing grafting with arterial conduit received a small-dose IV infusion of nitroglycerin until at least the morning after surgery. Postoperative electrocardiogram (ECG) monitoring was continued for a minimum of 3 days. All patients received heparin before surgery, either as an infusion or as subcutaneous injections. Antianginal drug treatment was not routinely restarted after surgery, although antihypertensive treatment was restarted at the discretion of the attending staff.
Data regarding risk factors commonly associated with perioperative mortality were collected (7–13). These were age; gender; preoperative creatinine concentration; preoperative hemoglobin concentration; body mass index; left main coronary artery stenosis; previous peripheral arterial surgery; myocardial infarction within 6 wk before surgery (defined as a diagnostic increase in creatinine kinase MB fraction or diagnostic changes in the ECG; history of cardiac surgery, preoperative use of an intraaortic balloon pump; and preoperative diagnosis of hypertension, diabetes (defined as diagnosis plus use of hypoglycemic medication), cerebrovascular disease (defined as stroke or transient ischemic attack or asymptomatic carotid stenosis), or chronic obstructive pulmonary disease undergoing treatment. The number of coronary vessels grafted was recorded as an indicator of the number of significant coronary vessels diseased. Patients requiring surgery within 24 h and patients who had not been admitted to the hospital specifically for cardiac surgery but who could not be discharged before cardiac surgery, were classified as urgent. Patients who had been admitted to the hospital specifically for cardiac surgery were classified as elective. Left ventricular dysfunction was graded according to wall motion analysis by a cardiologist after either angiography or echocardiography. The overall grade of left ventricular function used was normal, mildly impaired, moderately impaired, or severely impaired. The occurrence of concurrent cardiac or cardiovascular surgery (typically cardiac valve repair, valve replacement, carotid endarterectomy, or left ventricular aneurysmectomy) was recorded. Regular daily patient use of any dose of drugs in the following categories was re- corded: calcium antagonists, ß-blockers, angiotensin converting enzyme (ACE) inhibitors, aspirin (date of last aspirin consumption was also recorded), warfarin, digoxin, and long-acting nitrates (i.e., oral, topical, or iv). Patients receiving sublingual nitroglycerin "as required" were not considered to be taking regular nitrate therapy. Cardioactive or antithrombotic drugs taken by <5% of our surgical population, such as prazosin and dipyridamole, were not included in the model.
In-hospital deaths were defined as deaths before discharge from our institution. Discharge data were collected from hospital records after patient separation from hospital and were checked by one of the authors (WMW). A small proportion of patients, <5%, had missing data in the left ventricular function and preoperative creatinine fields. This was handled by coding these patients as having normal left ventricular function and mean creatinine, respectively.
All of the above drug and nondrug variables were entered as independent variables into a multiple logistic regression model with in-hospital mortality as the dependent variable. Relative risk of mortality and the standard error of the estimate for each variable were calculated from the ß-coefficients and the standard error of the ß-coefficients of the logistic regression equation (14). Stepwise selection of variables was not used. To examine the association of oral nitrates with in-hospital mortality, the analysis was performed again on the subset of patients remaining after exclusion of all patients on IV nitrates.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
We studied 1593 consecutive patients and 53 patients (3.3%) died before discharge from the hospital.
The mean age was 63.8 yr and 2.8% were >79 yr of age. Of the 125 patients undergoing concurrent cardiac or cardiovascular surgery, 105 underwent valve or aortic root surgery, 15 underwent carotid endarterectomy, and 5 underwent concurrent left ventricular aneurysmectomy. Of the 242 patients with a preoperative diagnosis of cerebrovascular disease, 34 had experienced symptomatic cerebral ischemia and had a proven carotid artery stenosis, 140 had experienced symptomatic cerebral ischemia without proven carotid artery stenosis, 140 had experienced symptomatic cerebral ischemia without proven carotid artery stenosis, and 68 had an asymptomatic carotid stenosis. The mean (range) hemoglobin concentration was 14.1 (7.9–18.9) g/dL, and mean body mass index was 27.1 (16.8–46.7) kg/m2. The mean creatinine concentration was 109 (40–1210) mmol/L, and seven patients were undergoing renal dialysis before surgery. Left main coronary artery stenosis was present in 27.1% of patients, the mean fractional occlusion was 60%. Only one patient was undergoing treatment with an intraaortic balloon pump; this variable was therefore excluded from analysis. There were 38 patients who underwent surgery without CPB. The remainder had a mean bypass time of 94 (19–376) min and a mean aortic cross-clamp time of 60 (0–231) min; 66.6% of patients had cold anterograde and retrograde blood cardioplegia, 33.4% had cold anterograde cardioplegia alone. There was a mean of 3.2 distal anastomoses per patient and at least one internal mammary artery was used in 80% of patients. A mean dose of 1.6 million units of aprotinin was given to 47% of patients. The median postoperative intubation time was 11 h.
The number of patients (mortality rate) taking each class of preoperative drug therapy was as follows: regular daily nitrates 959 (4.8%); ß-blockers 1162 (2.3%); calcium channel antagonists 684, (4.5%); ACE inhibitors 432 (3.7%); warfarin 92 (2.2%); aspirin within 5 days before surgery 936 (3.7%); and digoxin 128, (5.5%). In contrast, among patients not taking regular daily nitrates, the number of patients (mortality rate) was 634, (1.1%); among patients not taking ß-blockers, 431 (6.0%), among patients not taking calcium antagonists, 909 (2.4%); and among patients not taking ACE inhibitors, 1161, (3.2%).
The mortality rates (number of patients) among subgroups of the above classes were: oral nitrates 4.1% (790), topical nitrates 0% (25), IV nitrates 5.3% (56), IV nitrates concurrent with oral or topical nitrates 12.5% (88), metoprolol 2.8% (905), atenolol 0.9% (228) or other ß-blockers 0% (29), nifedipine 3.4% (264), diltiazem 5.4% (261), amlodipine 3.4% (87), other calcium antagonist 6.9% (72), captopril 6.2% (129), enalapril 1.6% (123), lisinopril 6.3% (63), and other ACE inhibitors 3.2% (117). Because of the relatively small numbers of deaths in each group, multivariate analysis by generic subgroup was not attempted.
Severe or moderate impairment of left ventricular function was present in 27% of patients receiving IV nitrates with or without oral or topical nitrates. All patients receiving IV nitrates were scheduled for urgent surgery.
In the intraoperative period, 3.5% of patients were given metoprolol, 11.9% of patients were given esmolol, and 0.6% of patients were given both; the mean dose of metoprolol was 4.2 mg, and the mean dose of esmolol was 95 mg. Nitroglycerin was given in varying doses by infusion to 80% of patients, typically 0.1–0.25 µg · kg-1 · min-1 was used for prophylaxis of mammary artery vasospasm, and doses larger than this were used to control hypertension. The mortality rate of patients receiving intraoperative ß-blockers was 3.8%, and the mortality rate of patients receiving intraoperative nitroglycerin was 3.6%.
Death occurred on the day of surgery in 17 patients, on the first or second postoperative day in 12 patients, within the first postoperative week in another 12 patients, and after the first postoperative week in 12 patients.
The relative risk of in-hospital mortality is shown in Table 1. The model r2 was 0.060 (P < 0.0001). The relative risk of in-hospital mortality in patients taking preoperative nitrate therapy was 3.8, with 95% confidence intervals between 1.5 and 9.6. When the same model was applied to the subset of patients remaining after exclusion of the 144 patients on IV nitrates, the relative risk of each variable was similar to the results in Table 1; in particular, the relative risk of in-hospital mortality in patients taking nitrates was 3.2, with 95% confidence intervals between 1.3 and 6.7.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
This study suggests that there is an association, independent of other recognized risk factors, between preoperative treatment with nitrates and increased in-hospital mortality after coronary artery surgery. This association is statistically and clinically significant; our estimate is a 3.8 times increase in risk, with confidence intervals of this estimate between 1.5 and 9.6. Furthermore, this association persists after excluding patients treated with IV nitrates.
There are several mechanisms that could explain increased mortality with nitrates. First, it has been suggested that continuous therapy with each of the nitrates used in this study may induce tolerance (15–17). This may lead to reduced effectiveness of perioperative nitrates: in particular, reduced vasodilation of internal mammary artery grafts (18), reduced inhibition of platelet aggregation (19), reduced enhancement of ischemic preconditioning (20), and enhanced sensitivity to vasoconstricting drugs (21,22). In addition to concerns about tolerance, the cessation of nitrate therapy may cause rebound coronary vasoconstriction (23) and worsening of myocardial ischemia (5,6). Although most of our patients received nitroglycerin during surgery, there is no reliable means of monitoring the clinical effect of nitroglycerin in each patient, and it is possible that the doses given were inadequate to prevent arterial vasospasm in some patients. Even when patients were given nitroglycerin by infusion, the infusion rate may have been frequently altered, and sometimes stopped; for instance, in response to hypotension.
This article is not the first to raise concerns about the safety of chronic nitrate therapy in patients with ischemic heart disease. Ishikawa et al. (24) performed a randomized study of 1004 postmyocardial infarct patients with an average follow-up of 18 mo; one group received long-acting oral or transdermal nitrates, and a control group received none. Both groups were allowed sublingual or IV nitrates as required. There were a number of methodological problems with the study (not double-blinded, lack of placebo control, significant treatment cross-over between groups); nevertheless, the results suggested a doubling of mortality risk in the nitrate group.
A second important finding of this study is an inverse association between mortality and the preoperative use of ß-blocking drugs. Other investigators have suggested improved survival with the use of ß-blockade in perioperative patients (25) and patients with ischemic heart disease (26,27). However, the relevance of these findings to the present study is not clear, because few of our patients had continuous ß-blocker therapy during the perioperative period. In fact, most would have experienced a period of ß-blocker withdrawal. It is possible that ß-blockers protect during revascularization and that the effects of ß-blocker withdrawal after revascularization are not serious. Regardless of this speculation, we believe that the present study supports the generally accepted practice of continuing treatment with ß-blockade until the morning of surgery in cardiac surgical patients.
The findings for other drugs are less clear. The preoperative use of calcium antagonists was associated with a relative risk of mortality of 1.1, with 95% confidence intervals between 0.6 and 2.1; therefore, our study does not have the power to exclude or confirm a clinically significant association between calcium antagonists and mortality. Similar comments can be made for ACE inhibitors, aspirin, warfarin, and digoxin.
Could nitrate therapy simply be a marker of disease that is not optimal for surgical repair? IV nitrates are generally given to patients with unstable angina, which has repeatedly been shown to be strongly associated with increased operative mortality. Oral nitrates are generally given to patients with anginal symptoms that are not controlled by other medications. It has previously been recognized that the severity of chest pain symptoms, with the exception of unstable angina, is not a strong associate of operative mortality after coronary artery surgery (7). Nevertheless, despite our attempts to control for the confounding effects of the severity of underlying disease using the risk prediction model, it is possible that the association between nitrate therapy and mortality is, in fact, due to differences in underlying disease, not to a deleterious effect of nitrate therapy. Similar considerations affect ß-blockers, which are less likely to be used in diabetics, patients with impaired myocardial function, and patients with chronic lung disease so that it is possible that, in this study, some residual confounding has occurred or that the use of ß-blockers marks disease that is advantageous for surgical repair.
Our initial motivation to study this subject came from the controversy surrounding calcium antagonists. We did not expect to find an association between nitrates or ß-blockers and mortality. Therefore, our results should be viewed as hypothesis-generating, rather than as hypothesis-testing, and they must be confirmed by a hypothesis-testing study. Because few of our patients received topical nitrates, we cannot comment on any association between topical nitrates and mortality. Those patients given oral nitrates received various doses of isosorbide mononitrate and isosorbide dinitrate at the discretion of their cardiologist, and it is possible that the association found in the present study does not apply to all formulations and dose schedules. Finally, as with all epidemiological studies, association does not prove causation.
Our findings support the view that the potential adverse effects of chronic nitrate treatment should be seriously considered, may cause impaired clinical outcome in the setting of cardiac surgery, and are worthy of further investigation. We cannot recommend that nitrate therapy be ceased before coronary artery surgery or that vasodilators, such as sodium nitroprusside, which are not affected by nitrate tolerance, should be chosen for intraoperative use in patients who have been exposed to chronic nitrate therapy. Regardless of whether nitrate therapy is causally associated with postoperative mortality, we think that it is important to recognize that preoperative nitrate therapy seems to be a marker of adverse outcome.
In conclusion, the results of this study suggest that regular daily nitrate therapy before coronary artery surgery is associated with an increased in-hospital mortality rate and that regular daily ß-blocker therapy is associated with reduced in-hospital mortality in patients undergoing coronary artery surgery. Further studies are required to investigate this association and to determine the best way to manage patients receiving nitrate therapy, and patients who are not taking ß-blockers, in the setting of coronary artery surgery.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
-
Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620–5.
[Abstract/Free Full Text] - Kostis JB, Clifton RL, Cosgrove NM, Wilson AC. Association of calcium channel blocker use with increased rate of acute myocardial infarction in patients with left ventricular dysfunction. Heart J 1997;133:550–7.
-
Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary artery disease. Circulation 1995;92:1326–31.
[Abstract/Free Full Text] - Kai H, Hideo Y, Mitsuru N, et al. Effects of continuous intravenous infusion of isosorbide dinitrate on development of tolerance to vasodilating action in human epicardial arteries. Am Heart J 1994;128:230–6.[Web of Science][Medline]
-
Parker JD, Parker AB, Farrell B, Parker JO. Intermittent transdermal nitroglycerin therapy: decreased anginal threshold during the nitrate-free period. Circulation 1995;91:973–8.
[Abstract/Free Full Text] -
Martsevich SY, Koutishenko N, Metelitsa VI. Abrupt cessation of short-term continuous treatment with isosorbide dinitrate may cause a rebound increase in silent myocardial ischemia in patients with stable myocardial pectoris. Heart 1996;75:447–50.
[Abstract/Free Full Text] - Kennedy JW, Kaiser GC, Fisher LD, et al. Multivariate discriminant analysis of the clinical and angiographic predictors of operative mortality from the collaborative study in coronary artery surgery (CASS). J Thorac Cardiovasc Surg 1980;80:876–87.[Abstract]
- Edwards FH, Clark RE, Schwartz M. Coronary artery bypass grafting: the Society of Thoracic Surgeons national database experience. Ann Thorac Surg 1994;57:12–9.[Abstract]
- Paiement B, Pelletier C, Dynda I, et al. A simple classification of the risk in cardiac surgery. Can Anaesth Soc J 1983;30:61–8.[Web of Science][Medline]
- Parsonnet V, Dean D, Bernstein AD. A method of uniform stratification of risk for evaluating the results of surgery in acquired adult heart disease. Circulation 1989;79 (Suppl I):3–12.[Web of Science]
-
Higgins TL, Estafanous FG, Loop FD, et al. Stratification of morbidity and mortality outcome by preoperative risk factors in coronary artery bypass patients: a clinical severity score. JAMA 1992;267:2344–8.
[Abstract/Free Full Text] - Iyer VS, Russel WJ, Peppard P, Craddock D. Mortality and myocardial infarction after coronary artery surgery: a review of 12003 patients. Med J Aust 1993;159:166–70.[Web of Science][Medline]
-
Tu JV, Haglal SB, Naylor CD. Multicenter validation of a risk index for mortality, intensive care unit stay, and overall hospital length of stay after cardiac surgery. Circulation 1995;91:677–84.
[Abstract/Free Full Text] - Morris JA, Gardner MJ. Calculating confidence intervals for relative risks, odds ratios, and standardised ratios and rates. In: Gardner MJ, Altman DG, eds. Statistics with confidence. London:BMJ 1992:50–63.
-
Ghio S, Poli A, Ferranria M, et al. Hemodynamic effects of glyceryl trinitrate during continuous 24 hour infusion in patients with heart failure. Br Heart J 1994;72:145–9.
[Abstract/Free Full Text] -
Norlander R, Ealter M. Once versus twice daily administration of controlled release isosorbide-5-mononitrate in the treatment of stable angina pectoris. Eur Heart J 1994;15:108–13.
[Abstract/Free Full Text] - Mehra A, Shotan A, Ontrrzega E, et al. Escalating nitrate dose overcomes early attenuation of hemodynamic effect caused by nitrate tolerance in patients with heart failure. Am Heart J 1995;130:798–805.[Web of Science][Medline]
- Du ZY, Buxton BF, Woodman OL. Tolerance to glyceryl trinitrate in isolated human internal mammary arteries. J Thorac Cardiovasc Surg 1992;104:1280–4.[Abstract]
- Chirkov YY, Chirkova LP, Horowitz JD. Nitroglycerin tolerance at the platelet level in patients with angina pectoris. Am J Cardiol 1997;80:128–31.[Web of Science][Medline]
- Szilvassy Z, Ferdinandy P, Bor P, et al. Loss of preconditioning in rabbits with vascular tolerance to nitroglycerin. Pharmacol 1994;112:999–1001.
- Zierhut W, Ball HA. Prevention of vascular nitroglycerin tolerance by inhibition of protein kinase C. Br J Pharmacol 1996;119:3–5.[Web of Science][Medline]
-
Munzel T, Giaid A, Kurz S, et al. Evidence for a role of endothelin-1 and protein kinase C in nitrate tolerance. Natl Acad Sci USA 1995;92:5244–8.
[Abstract/Free Full Text] -
Munzel Y, Bassenge E. Long-term angiotensin-converting enzyme inhibition with high-dose enalapril retards nitrate tolerance in large epicardial arteries and prevents rebound coronary vasoconstriction in vivo. Circulation 1996;93:2052–8.
[Abstract/Free Full Text] - Ishikawa K, Kanamasa K, Ogawa I, et al. Long term nitrate treatment increases cardiac events in patients with healed myocardial infarction. Jpn Circ J 1996;60:779–88.[Medline]
-
Mangano DT, Lavug EL, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. N Engl J Med 1996;335:1713–20.
[Abstract/Free Full Text] -
Soumerai SB, McLaughlin TJ, Speigelman D, et al. Adverse outcomes of underuse of ß-blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277:115–21.
[Abstract/Free Full Text] - Barron HV, Viskin S, Lundstrom RJ, et al. Effect of ß-adrenergic blocking agents on mortality rate in patients not revascularised after myocardial infarction: data from a large HMO. Am Heart J 1997;134:608–13.[Web of Science][Medline]
This article has been cited by other articles:
|
|
 |
|
  A. Miceli, R. Capoun, C. Fino, P. Narayan, A. J. Bryan, G. D. Angelini, and M. Caputo Effects of Angiotensin-Converting Enzyme Inhibitor Therapy on Clinical Outcome in Patients Undergoing Coronary Artery Bypass Grafting J. Am. Coll. Cardiol., November 3, 2009; 54(19): 1778 - 1784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Bell, G. K. Grunwald, J. H. Baltz, G. O. McDonald, M. R. Bell, F. L. Grover, and A. L. W. Shroyer Does Preoperative Hemoglobin Independently Predict Short-Term Outcomes After Coronary Artery Bypass Graft Surgery? Ann. Thorac. Surg., November 1, 2008; 86(5): 1415 - 1423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Wijeysundera, W. S. Beattie, V. Rao, J. Ivanov, and K. Karkouti Calcium antagonists are associated with reduced mortality after cardiac surgery: a propensity analysis J. Thorac. Cardiovasc. Surg., March 1, 2004; 127(3): 755 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Srinivasan, M. J. Shackcloth, A. D. Grayson, and B. M. Fabri Preoperative {beta}-blocker therapy in coronary artery bypass surgery: a propensity score analysis of outcomes Interactive CardioVascular and Thoracic Surgery, December 1, 2003; 2(4): 495 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. B. Ferguson Jr, E. D. Peterson, L. P. Coombs, M. C. Eiken, M. L. Carey, F. L. Grover, and E. R. DeLong Use of Continuous Quality Improvement to Increase Use of Process Measures in Patients Undergoing Coronary Artery Bypass Graft Surgery: A Randomized Controlled Trial JAMA, July 2, 2003; 290(1): 49 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. N. Wijeysundera, W. S. Beattie, V. Rao, and J. Karski Calcium antagonists reduce cardiovascular complications after cardiac surgery: A meta-analysis J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1496 - 1505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Chesebro, V. Fuster, F. J. Pugo, W. Karzai, H.-J. Priebe, and D. T. Mangano Aspirin and Mortality from Coronary Bypass Surgery N. Engl. J. Med., March 13, 2003; 348(11): 1057 - 1059. [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. C. ten Broecke, S. G. De Hert, E. Mertens, and H. F. Adriaensen Effect of preoperative {beta}-blockade on perioperative mortality in coronary surgery Br. J. Anaesth., January 1, 2003; 90(1): 27 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Fillinger, S. D. Surgenor, G. S. Hartman, C. Clark, T. M. Dodds, A. J. Rassias, W. C. Paganelli, P. Marshall, D. Johnson, D. Kelly, et al. The Association Between Heart Rate and In-Hospital Mortality After Coronary Artery Bypass Graft Surgery Anesth. Analg., December 1, 2002; 95(6): 1483 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Geraci and C. K. Haan Effect of beta blockers after coronary artery bypass in postinfarct patients: what can we learn from available literature? Ann. Thorac. Surg., November 1, 2002; 74(5): 1727 - 1732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. B. Ferguson Jr, L. P. Coombs, E. D. Peterson, and for the Society of Thoracic Surgeons National Adul Preoperative {beta}-Blocker Use and Mortality and Morbidity Following CABG Surgery in North America JAMA, May 1, 2002; 287(17): 2221 - 2227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Costa, R. G. Carere, S. V. Lichtenstein, D. P. Foley, V. de Valk, W. Lindenboom, P. C.H. Roose, T. R. van Geldorp, C. Macaya, J. L. Castanon, et al. Incidence, Predictors, and Significance of Abnormal Cardiac Enzyme Rise in Patients Treated With Bypass Surgery in the Arterial Revascularization Therapies Study (ARTS) Circulation, November 27, 2001; 104(22): 2689 - 2693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kaneko, Y. Saito, Y. Hikawa, K. Yasuda, and K. Makita Dose-dependent prophylactic effect of nicorandil, an ATP-sensitive potassium channel opener, on intra-operative myocardial ischaemia in patients undergoing major abdominal surgery Br. J. Anaesth., March 1, 2001; 86(3): 332 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Weightman and M. A. J. Newman Drug therapy before coronary artery operations J. Thorac. Cardiovasc. Surg., November 1, 1999; 118(5): 979 - 979. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
